Similarly, in SURMOUNT-4 (tirzepatide), participants completed a 36-week open-label lead-in to 10 or 15 mg, after which they were randomized to continue tirzepatide or switch abruptly to placebo
This study was supported by NIH grants R01 DK116004 (GL) and R01 DK094871 (GL), start-up funds (GL), American Heart Association (AHA) postdoctoral fellowship 23POST1026084 (AS), Biotechnology and Biological Sciences Research Council grant BB/M020991/1 (SCS), and New Life Foundation grant 14-15/20 (SCS)
Its focused action provides clear, interpretable data without the confounding variables that come from activating multiple systems at once
Others may need dosage adjustments or complementary strategies like increased protein intake, hydration, and micronutrient monitoring to sustain energy
doi: 10.1016/j.pnpbp.2020.109951 444 R.a.P